These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34668558)

  • 1. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
    Monge-Maillo B; Norman FF; Chamorro-Tojeiro S; Gioia F; Pérez-Molina JA; Chicharro C; Moreno J; López-Vélez R
    J Travel Med; 2022 Nov; 29(7):. PubMed ID: 34668558
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of miltefosine responsive pleomorphic post kala-azar dermal leishmaniasis.
    Pal D; Naskar A; Ghosh MK
    Braz J Infect Dis; 2013; 17(5):610-2. PubMed ID: 24012431
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
    Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
    Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient.
    Ramos A; Cruz I; Muñez E; Salas C; Fernández A; Alvarez-Espejo T
    Infection; 2008 Mar; 36(2):184-6. PubMed ID: 18327683
    [No Abstract]   [Full Text] [Related]  

  • 5. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
    Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
    Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced case of PKDL due to delayed treatment: A rare case report.
    Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-kala-azar dermal leishmaniasis caused by Leishmania infantum in an immunocompetent patient.
    Sánchez-Albisua B; Polimón I; Pérez-Tato B; Marinero S; Fernández-López P
    Int J Dermatol; 2013 Jul; 52(7):897-9. PubMed ID: 23675968
    [No Abstract]   [Full Text] [Related]  

  • 10. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
    Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE
    Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
    Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
    Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
    Jaiteh MB; İnkaya AÇ; Üner A; Elçin G; Ergüven S; Kurtulan O; Harxhi A; Akova M
    Parasitol Int; 2021 Feb; 80():102197. PubMed ID: 32920054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An unusual paediatric case of post-kala-azar dermal leishmaniasis: a hidden parasite under the veil of white.
    Arora A; Mohta A
    Clin Microbiol Infect; 2023 Jun; 29(6):803-804. PubMed ID: 36918142
    [No Abstract]   [Full Text] [Related]  

  • 15. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
    Ramesh V; Avishek K; Sharma V; Salotra P
    Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Pandey K; Pal B; Topno RK; Lal CS; Das VNR; Das P
    Rev Soc Bras Med Trop; 2020; 54():e20200208. PubMed ID: 33338118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 19. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
    Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
    BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.